search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


NOSTRADAMUS: Testing for thrombophilia in patients with a first episode of venous thromboembolism (VTE): a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs.


- candidate number2267
- NTR NumberNTR784
- ISRCTNISRCTN07836779
- Date ISRCTN created28-dec-2006
- date ISRCTN requested18-dec-2006
- Date Registered NTR27-sep-2006
- Secondary IDsN/A 
- Public TitleNOSTRADAMUS: Testing for thrombophilia in patients with a first episode of venous thromboembolism (VTE): a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs.
- Scientific TitleNOSTRADAMUS: Testing for thrombophilia in patients with a first episode of venous thromboembolism: a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs.
- ACRONYMNOSTRADAMUS
- hypothesisTesting for thrombophilia after a first episode of VTE with subsequent prolongation of anticoagulant treatment in thrombophilic patients is beneficial in terms of clinical outcomes, quality of life, and costs.
- Healt Condition(s) or Problem(s) studiedPulmonary embolism, Deep vein thrombosis
- Inclusion criteria1. Subjects must be willing and able to give written informed consent
2. Confirmed symptomatic DVT, i.e., proximal vein or extensive calf-vein thrombosis, involving at least the upper third part of the deep calf veins (trifurcation, AND/OR confirmed symptomatic PE, no longer than 2 months prior to randomization
3. age 18 years or older
- Exclusion criteria1. Previous episodes of DVT or PE
2. Active bleeding or high risk for bleeding contraindicating treatment with LMWH, fondaparinux or VKA
3. Insertion of a caval filter to treat the episode of VTE
4. Active cancer or anti-cancer treatment in the 6 months prior to the acute episode of VTE
5. Life expectancy < 18 months
6. Arterial thrombotic events in the context of a confirmed antiphospholipid antibody syndrome
7. Indications for VKA other than DVT
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type[default]
- Studytypeintervention
- planned startdate 1-okt-2006
- planned closingdate1-apr-2010
- Target number of participants1336
- InterventionsRandomization between disclosure and undisclosure of results of thrombophilia screening and subsequent additional anticoagulant treatment for a predefined period will be installed in those in whom thrombophilia is detected in the disclosure group
- Primary outcomerecurrent VTE 18 months after the acute episode of VTE
- Secondary outcome1. Recurrent VTE at the end of the study
2. A composite endpoint of recurrent VTE and bleeding at the end of the study
3. Quality of life
4. costs of testing and subsequent predefined prolongation of anticoagulant therapy
- Timepoints
- Trial web siteN/A
- statusstopped
- CONTACT FOR PUBLIC QUERIESDr. S. Middeldorp
- CONTACT for SCIENTIFIC QUERIESDr. S. Middeldorp
- Sponsor/Initiator Academic Medical Center (AMC), Department of Vascular Medicine
- Funding
(Source(s) of Monetary or Material Support)
ZON-MW, The Netherlands Organization for Health Research and Development, Netherlands Heart Foundation (NHS, Nederlandse Hartstichting)
- PublicationsN/A
- Brief summaryA randomized controlled trial of testing and no testing for thrombophilia in patients with a first episode of VTE will be performed. Subsequent additional anticoagulant treatment for a predefined period will be installed in those in whom thrombophilia is detected in the testing group, while others will receive a standard predefined duration of treatment. In addition, the impact on quality of life of thrombophilia testing will be measured. Efficacy and safety outcomes are risk for recurrent VTE and clinically important bleeding (also as a composite outcome). Other outcomes are overall quality of life and costs associated with the outcome measures 18 months after the initial episode of VTE. Outcomes will be compared between thrombophilic patients allocated to the testing group and to the no testing group. A total of 1336 patients will have to be included to detect a benefit of 90% by prolonging anticoagulant treatment in patients with thrombophilia while on treatment, and no reduction in the 6 months after cessation of treatment (overall RRR 55%) [power 80%, CI 95%].
- Main changes (audit trail)
- RECORD27-sep-2006 - 25-jan-2008


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl